AVTX Stock - Avalo Therapeutics, Inc.
Unlock GoAI Insights for AVTX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $441,000 | $1.92M | $18.05M | $5.40M | $6.70M |
| Gross Profit | $807,000 | $640,000 | $14.62M | $3.91M | $6.40M |
| Gross Margin | 183.0% | 33.3% | 81.0% | 72.4% | 95.5% |
| Operating Income | $-68,512,000 | $-27,351,000 | $-37,440,000 | $-82,134,000 | N/A |
| Net Income | $-35,129,000 | $-31,544,000 | $-41,658,000 | $-84,376,000 | $-63,500,000 |
| Net Margin | -7965.8% | -1639.5% | -230.8% | -1563.1% | -947.9% |
| EPS | $-4.32 | $-113.58 | $-1062.65 | $-2330.66 | $-2523.77 |
Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as inflammatory bowel disease, including moderate to severe Crohn's disease, and ulcerative colitis; and Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome. The company also engages in developing AVTX-007, a fully human Anti-IL-18 monoclonal antibody that is under Phase I clinical trial for the treatment of still's disease, including adult-onset still's disease and systemic juvenile idiopathic arthritis. Its products for rare genetic diseases in Phase III clinical trials include AVTX-801, a D-galactose substrate replacement therapy for the treatment of phosphoglucomutase 1 deficiency (PGM1), also known as PGM1-CDG; and AVTX-803, a L-fucose substrate replacement therapy for the treatment of LADII, also known as SLC35C1-CDG. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 18th 2025 | Mizuho | Initiation | Outperform | $39 |
| September 17th 2025 | H.C. Wainwright | Reiterated | Buy | $25← $15 |
| September 5th 2025 | TD Cowen | Initiation | Buy | - |
| August 15th 2025 | Cantor Fitzgerald | Initiation | Overweight | - |
| June 2nd 2025 | H.C. Wainwright | Resumed | Buy | $15 |
| March 25th 2025 | Stifel | Initiation | Buy | $36 |
| March 25th 2025 | Jefferies | Initiation | Buy | $23 |
| February 28th 2025 | Piper Sandler | Initiation | Overweight | $48 |
| February 21st 2025 | Wedbush | Initiation | Outperform | $18 |
| December 19th 2024 | BTIG Research | Initiation | Buy | $40 |
| October 24th 2024 | H.C. Wainwright | Initiation | Neutral | - |
| April 16th 2024 | Oppenheimer | Upgrade | Outperform | $35 |
Earnings History & Surprises
AVTXEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q1 2026 | Mar 19, 2026 | $-1.54 | — | — | — |
Q4 2025 | Nov 6, 2025 | $-1.67 | $-2.19 | -31.1% | ✗ MISS |
Q3 2025 | Aug 7, 2025 | $-1.43 | $-1.92 | -34.3% | ✗ MISS |
Q2 2025 | May 12, 2025 | $-1.07 | $-1.25 | -16.8% | ✗ MISS |
Q1 2025 | Mar 20, 2025 | $-0.39 | $-7.95 | -1938.5% | ✗ MISS |
Q4 2024 | Nov 7, 2024 | $-1.19 | $-2.83 | -137.8% | ✗ MISS |
Q3 2024 | Aug 12, 2024 | $-6.70 | $-14.07 | -110.0% | ✗ MISS |
Q2 2024 | May 13, 2024 | $-1.18 | $-5.98 | -406.8% | ✗ MISS |
Q1 2024 | Mar 29, 2024 | $-4.80 | $-116.21 | -2321.0% | ✗ MISS |
Q4 2023 | Nov 9, 2023 | $-261.90 | $-26.19 | +90.0% | ✓ BEAT |
Q3 2023 | Aug 3, 2023 | $-214.29 | $-140.48 | +34.4% | ✓ BEAT |
Q2 2023 | May 4, 2023 | $-230.95 | $-202.38 | +12.4% | ✓ BEAT |
Q1 2023 | Mar 29, 2023 | $-123.81 | $-247.62 | -100.0% | ✗ MISS |
Q4 2022 | Nov 7, 2022 | $-245.24 | $80.95 | +133.0% | ✓ BEAT |
Q3 2022 | Aug 4, 2022 | $-428.57 | $-328.57 | +23.3% | ✓ BEAT |
Q2 2022 | May 5, 2022 | $-400.16 | $-571.66 | -42.9% | ✗ MISS |
Q1 2022 | Mar 2, 2022 | $-1.90 | $-1.92 | -1.1% | ✗ MISS |
Q4 2021 | Nov 9, 2021 | $-543.07 | $-485.91 | +10.5% | ✓ BEAT |
Q3 2021 | Aug 2, 2021 | $-2.04 | $-2.16 | -5.9% | ✗ MISS |
Latest News
Mizuho Initiates Coverage On Avalo Therapeutics with Outperform Rating, Announces Price Target of $39
📈 PositiveAvalo Therapeutics Q3 EPS $(2.19) Misses $(1.61) Estimate
📉 NegativeAvalo Therapeutics Has Completed Enrollment In Its Phase 2 LOTUS trial of AVTX-009 For Hidradenitis Suppurativa, Exceeding The Target Enrollment Of 222 Patients With Approximately 250 Patients Enrolled. Topline Data Expected In Mid-2026
📈 PositiveHC Wainwright & Co. Maintains Buy on Avalo Therapeutics, Raises Price Target to $25
📈 PositiveFrequently Asked Questions about AVTX
What is AVTX's current stock price?
What is the analyst price target for AVTX?
What sector is Avalo Therapeutics, Inc. in?
What is AVTX's market cap?
Does AVTX pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to AVTX for comparison